Reduced incidence of AD with NSAID but not H2receptor antagonists: The Cache County Study
The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Previous analyses from the Cache County (UT) Study showed inverse associations between the prevalence of AD and the use of nonsteroidal anti-inflammatory drugs (NSAID), aspirin compounds, or histamine H(2) receptor antagonists (H(2)RA). The authors re-examined these associations using data on incident AD. METHODS: In 1995 to 1996, elderly (aged 65+) county residents were assessed for dementia, with current and former use of NSAID, aspirin, and H(2)RA as well as three other "control" medication classes also noted. Three years later, interval medication histories were obtained and 104 participants with incident AD were identified among 3,227 living participants. Discrete time survival analyses estimated the risk of incident AD in relation to medication use. RESULTS: AD incidence was marginally reduced in those reporting NSAID use at any time. Increased duration of use was associated with greater risk reduction, and the estimated hazard ratio was 0.45 with >/=2 years of exposure. Users of NSAID at baseline showed little reduction in AD incidence, regardless of use thereafter. By contrast, former NSAID users showed substantially reduced incidence (estimated hazard ratio = 0.42), with a trend toward greatest risk reduction among those with extended exposure. Similar patterns appeared with aspirin but not with any other medicines examined. CONCLUSIONS: Long-term NSAID use may reduce the risk of AD, provided such use occurs well before the onset of dementia. More recent exposure seems to offer little protection. Recently initiated randomized trials of NSAID for primary prevention of AD are therefore unlikely to show effects with treatment until participants have been followed for several years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
(1987) · PubMed · Cited by 2,657
Allison, P. (1984) · Sage eBooks · doi:10.4135/9781412984195 · Cited by 2,150
Event History Analysis : Regression for Longitudinal Event Data
Allison, P. D. (1984) · Cited by 1,711
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388
McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367
Jorm, A. F. (1994) · Psychological Medicine · doi:10.1017/s003329170002691x · Cited by 1,204
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
Education and the prevalence of dementia and Alzheimer's disease
Katzman, R. (1993) · Neurology · doi:10.1212/wnl.43.1_part_1.13 · Cited by 1,159
Risk of Alzheimer's disease and duration of NSAID use
Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997) · Neurology · doi:10.1212/wnl.48.3.626 · Cited by 1,132
Clinical trial of indomethacin in Alzheimer's disease
Rogers, J., Kirby, L. C., Hempelman, S. R., Berry, D. L., McGeer, P. L., Kaszniak, A. W., Zalinski, J., Cofield, M., Mansukhani, L., Willson, P., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1609 · Cited by 999
Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease
Lim, G. P., Yang, F., Chu, T., Chen, P., Beech, W., Teter, B., Tran, T., Ubeda, O., Ashe, K. H., Frautschy, S. A., et al. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-15-05709.2000 · Cited by 884
Breitner, J. C. S., Gau, B. A., Welsh, K. A., Plassman, B. L., McDonald, W. M., Helms, M. J., & Anthony, J. C. (1994) · Neurology · doi:10.1212/wnl.44.2.227 · Cited by 568
Self-citationAlzheimer's disease: A study of epidemiological aspects
Heyman, A., Wilkinson, W. E., Stafford, J. A., Helms, M. J., Sigmon, A. H., & Weinberg, T. (1984) · Annals of Neurology · doi:10.1002/ana.410150406 · Cited by 525
Rockwood, K., Kirkland, S., Hogan, D. B., MacKnight, C., Merry, H., Verreault, R., Wolfson, C., & McDowell, I. (2002) · Archives of Neurology · doi:10.1001/archneur.59.2.223 · Cited by 516
Breitner, J. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00049-k · Cited by 466
Self-citationA randomized controlled trial of prednisone in Alzheimer’s disease
Aisen, P. S., Davis, K. L., Berg, J. D., Schafer, K., Campbell, K., Thomas, R. G., Weiner, M. F., Farlow, M. R., Sano, M., Grundman, M., et al. (2000) · Neurology · doi:10.1212/wnl.54.3.588 · Cited by 464
Nonsteroidal anti-inflammatory drugs in Alzheimer's disease
Rich, J. B., Rasmusson, D. X., Folstein, M. F., Carson, K. A., Kawas, C., & Brandt, J. (1995) · Neurology · doi:10.1212/wnl.45.1.51 · Cited by 446
A case‐control study of Alzheimer's disease in Australia
Broe, G. A., Henderson, A. S., Creasey, H., McCusker, E., Korten, A. E., Jorm, A. F., Longley, W., & Anthony, J. C. (1990) · Neurology · doi:10.1212/wnl.40.11.1698 · Cited by 445
Self-citationAnti-inflammatory drugs and Alzheimer disease
Mcgeer, P., Mcgeer, E., Rogers, J., & Sibley, J. (1990) · The Lancet · doi:10.1016/0140-6736(90)91101-f · Cited by 437
APOE -ε4 count predicts age when prevalence of AD increases, then declines: The Cache County Study
Breitner, J. C. S., Wyse, B. W., Anthony, J. C., Welsh-Bohmer, K. A., Steffens, D. C., Norton, M. C., Tschanz, J. T., Plassman, B. L., Meyer, M. R., Skoog, I., et al. (1999) · Neurology · doi:10.1212/wnl.53.2.321 · Cited by 397
Self-citationA double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease
Scharf, S., Mander, A., Ugoni, A., Vajda, F., & Christophidis, N. (1999) · Neurology · doi:10.1212/wnl.53.1.197 · Cited by 390
A randomized controlled trial of prednisone in Alzheimer’s disease
Koch, H. J., & Szecsey, A. (2000) · Neurology · doi:10.1212/wnl.55.7.1067 · Cited by 384
Incidence of AD may decline in the early 90s for men, later for women: The Cache County study
Miech, R. A., Breitner, J. C. S., Zandi, P. P., Khachaturian, A. S., Anthony, J. C., & Mayer, L. (2002) · Neurology · doi:10.1212/wnl.58.2.209 · Cited by 331
Self-citationThe Canadian Study of Health and Aging *: Risk factors for Alzheimer's disease in Canada
Aging, T. C. S. O. H. A. (1994) · Neurology · doi:10.1212/wnl.44.11.2073 · Cited by 295
Andersen, K., Launer, L. J., Ott, A., Hoes, A. W., Breteler, M. M. B., & Hofman, A. (1995) · Neurology · doi:10.1212/wnl.45.8.1441 · Cited by 285
A CASE-CONTROL STUDY OF DEMENTIA OF THE ALZHEIMER TYPE
FRENCH, L. R., SCHUMAN, L. M., MORTIMER, J. A., HUTTON, J. T., BOATMAN, R. A., & CHRISTIANS, B. (1985) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a114013 · Cited by 244
A case‐control study of Alzheimer's disease
Graves, A. B., White, E., Koepsell, T. D., Reifler, B. V., Van Belle, G., Larson, E. B., & Raskind, M. (1990) · Annals of Neurology · doi:10.1002/ana.410280607 · Cited by 237
Hewett, S. J., Uliasz, T. F., Vidwans, A. S., & Hewett, J. A. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39251-1 · Cited by 227
Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: The Cache County Study
Anthony, J. C., Breitner, J. C. S., Zandi, P. P., Meyer, M. R., Jurasova, I., Norton, M. C., & Stone, S. V. (2000) · Neurology · doi:10.1212/wnl.54.11.2066 · Cited by 224
Self-citationVan Gool, W. A., Weinstein, H. C., Scheltens, P. K., & Walstra, G. J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05623-9 · Cited by 212
(1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.10.1279 · Cited by 207
Breteler, M. M. B., Van Duijn, C. M., Chandra, V, Fratiglioni, L., Graves, A. B., Heyman, A., Jorm, A. F., Kokmen, E., Kondo, K., Mortimer, J. A., et al. (1991) · International Journal of Epidemiology · doi:10.1093/ije/20.supplement_2.s36 · Cited by 181
Pasinetti, G. M. (1998) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19981001)54:1<1::aid-jnr1>3.0.co;2-m · Cited by 170
History of aspirin and its mechanism of action.
Vane, J. R., Flower, R. J., & Botting, R. M. (1990) · PubMed · Cited by 170
Anti-inflammatory Drugs Protect Against Alzheimer Disease at Low Doses
Broe, G. A., Grayson, D. A., Creasey, H. M., Waite, L. M., Casey, B. J., Bennett, H. P., Brooks, W. S., & Halliday, G. M. (2000) · Archives of Neurology · doi:10.1001/archneur.57.11.1586 · Cited by 160
NSAIDs and incident Alzheimer’s disease. The Rotterdam study
In ’t Veld, B. A., Launer, L. J., Hoes, A. W., Ott, A., Hofman, A., Breteler, M. M. B., & Stricker, B. H. C. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00096-7 · Cited by 145
Rheumatold Arthritis and Senile Dementia of the Alzhelmer's Type
JENKINSON, M. L., BLISS, M. R., BRAIN, A. T., & SCOTT, D. L. (1989) · Rheumatology · doi:10.1093/rheumatology/28.1.86-b · Cited by 143
Beard, C. M., Waring, S. C., O'Brien, P. C., Kurland, L. T., & Kokmen, E. (1998) · Mayo Clinic Proceedings · doi:10.4065/73.10.951 · Cited by 114
Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence
Zandi, P. P., & Breitner, J. C. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00297-4 · Cited by 108
Self-citationA case‐control study of Alzheimer's disease in China
Li, G., Shen, Y. C., Li, Y. T., Chen, C. H., Zhau, Y. W., & Silverman, J. M. (1992) · Neurology · doi:10.1212/wnl.42.8.1481 · Cited by 104
Alzheimer's Disease and Rheumatoid Arthritis
Myllykangas-Luosujärvi, R., & Isomäki, H. A. (1994) · Lara D. Veeken · doi:10.1093/rheumatology/33.5.501 · Cited by 82
Nonsteroidal antiinflammatory drug use in Alzheimer's disease
Lucca, U., Tettamanti, M., Forloni, G., & Spagnoli, A. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)90598-3 · Cited by 75
Performance characteristics of a two-stage dementia screen in a population sample
Khachaturian, A. S., Gallo, J. J., & Breitner, J. C. S. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(99)00196-1 · Cited by 75
Self-citationFalse-positive results with PCR to detect leukaemia-specific transcript
Hughes, T. P., Janssen, J. W. G., Morgan, G. J., Martiat, P., Saglio, G. N., Pignon, J., Pignatti, F., Mills, K., Keating, A., Gluckman, É., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)91102-g · Cited by 73
Aspirin, anti-inflammatory drugs and risk of dementia.
Henderson, A. S., Jorm, A. F., Christensen, H. M., Jacomb, P. A., & Korten, A. E. (1997) · PubMed · Cited by 68
Aspirin, anti-inflammatory drugs and risk of dementia
Henderson, A. S., Jorm, A. F., Christensen, H. M., Jacomb, P. A., & Korten, A. E. (1997) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(199709)12:9<926::aid-gps665>3.0.co;2-y · Cited by 50
Fourrier, A., Letenneur, L., Bégaud, B., & Dartigues, J. (1996) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(96)00202-8 · Cited by 43
Apolipoprotein E and cognitive decline in Alzheimer's disease
Plassman, B. L., & Breitner, J. C. S. (1996) · Neurology · doi:10.1212/wnl.47.2.317 · Cited by 41
Self-citationRheumatoid arthritis and susceptibility to Alzheimer's disease
Beard, C. M., KOKMAN, E., & Kurland, L. (1991) · The Lancet · doi:10.1016/0140-6736(91)93122-p · Cited by 35
Histamine H2 Blocking Drugs and the Risk for Alzheimer’s Disease: The Rotterdam Study
Launer, L. J., Jama, J. W., Ott, A., Breteler, M. M. B., Hoes, A. W., & Hofman, A. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00010-9 · Cited by 21
Rheumatoid arthritis and senile dementia of the Alzheimer's type
Jenkinson, M., Bliss, M., Brain, A., & Scott, D. (1989) · HighWire Press Open Archive · Cited by 7
Cited by
Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336
Histamine in the Nervous System
Haas, H. L., Sergeeva, O. A., & Selbach, O. (2008) · Physiological Reviews · doi:10.1152/physrev.00043.2007 · Cited by 1,228
The metabolic syndrome, inflammation, and risk of cognitive decline
Yaffe, K. (2004) · JAMA · doi:10.1001/jama.292.18.2237 · Cited by 1,025
“Current statin use 132 (10) 118 (18) 37 (12) 62 (18) .”
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975
Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer’s disease
Bartzokis, G. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.03.001 · Cited by 968
“Within the developmental framework of the model, these dynamic and interrelated age-related changes in membrane lipids can help explain why treatments that lower cholesterol, blood pressure, inflammation, or replace declining hormone levels in mid-life are associated with reduced risk of developing AD in later life bu…”
Background
Metadata
- Authors
- Zandi, P. P., Anthony, J. C., Hayden, K. M., Mehta, K., Mayer, L., & Breitner, J. C. S.
- Venue
- Neurology
- Published
- 2002-09-24
- Volume
- 59
- Issue
- 6
- Pages
- 880-886
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2041355017
- Cited by
- 316
- References
- 53
- FWCI
- 16.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.